CAM
VIRX

Cormorant Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Cormorant Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,862
Closed -$2.13M – 78
2017
Q1 		$2.13M Sell
14,862
-13,709
-48% -$1.96M 0.31% 59
2016
Q4 		$3.62M Buy
+28,571
New +$3.98M 0.49% 46

Other funds holding VIRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Cormorant Asset Management's VIRX Position: Q2 2017 in Review

Cormorant Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2017, closing a stake of 14,862 shares — an estimated $2.13M sold.

Cormorant Asset Management first reported a position in VIRX in Q4 2016 and held it in 2 quarters. The position peaked at $3.62M in Q4 2016. 37 funds tracked by Wall St. Rank hold VIRX as of Q2 2017.

  • Cormorant Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Cormorant Asset Management sold 14,862 Viracta Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $2.13M.
  • Cormorant Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Cormorant Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $3.62M in Q4 2016.
  • 37 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.